Story perspectives

Promising Gene Therapy MYR-101 Shows Hope for Canavan Disease

9/18/2025

50 6

Summary

Story summary

Canavan disease (CD) is a fatal genetic disorder caused by mutations in the ASPA gene, resulting in severe neurological problems.
MYR-101, a gene therapy targeting oligodendrocytes, shows promise in a Phase I/II trial, improving white matter and enzyme activity.
Patients experienced over 80% reduction in CSF NAA concentration and better developmental scores 12-24 months post-treatment.
Regulatory agencies recognize the therapy's potential for rare diseases.
A gene therapy trial for STXBP1 encephalopathy was paused after a patient’s death.

1 of 1

Story summary

Canavan disease (CD) is a fatal genetic disorder caused by mutations in the ASPA gene, resulting in severe neurological problems.
MYR-101, a gene therapy targeting oligodendrocytes, shows promise in a Phase I/II trial, improving white matter and enzyme activity.
Patients experienced over 80% reduction in CSF NAA concentration and better developmental scores 12-24 months post-treatment.
Regulatory agencies recognize the therapy's potential for rare diseases.
A gene therapy trial for STXBP1 encephalopathy was paused after a patient’s death.